Evercore ISI initiates Butterfly Network stock with outperform rating
Evercore ISI initiated coverage on Butterfly Network (NYSE: BFLY) with an outperform rating and $15.00 price target, citing its ultrasound-on-chip technology and growth potential. The firm projects $550M+ revenue by 2030 and positive EBITDA by 2028. BFLY stock has risen 367% over the past year, trading at $9.15 with a $2.44B market cap. Q2 2026 results showed a smaller loss than expected but lower revenue. Needham also initiated coverage with a buy rating and $10.00 target.
How this was made
The 30-second read
Why it matters
Analyst initiations provide a new catalyst that could move the stock beyond the recent earnings reaction.
Market read
New analyst coverage on BFLY offers a short‑term trading opportunity.
What to watch
Revenue miss in Q2 and ongoing cash burn could limit upside if new partnerships lag.
Background
Butterfly Network reported Q2 2026 results with a revenue miss but beat EPS expectations; the article adds fresh analyst coverage and price targets.
Ticker impact
Evercore ISI initiated coverage on Butterfly Network with an outperform rating and a $15 price target, and Needham also initiated coverage with a buy rating and a $10 target.
upward pressure as traders price in the new outperform rating and higher target
Both Evercore ISI and Needham are reputable research firms; their fresh initiations and higher price targets provide a clear catalyst for short‑term buying.
Market effects
Positive outlook for the handheld ultrasound and medical chip licensing sector may lift peers.
US biotech and med‑tech investors may increase exposure to similar companies.
Limited to US‑listed med‑tech space; no broader macro impact.
Counterpoint
The stock may be overvalued at $9.15 versus the $15 target; price could correct if growth expectations are not met.
Key entities
- Research FirmEvercore ISI
Initiated coverage with outperform rating and $15 target.
- Research FirmNeedham
Initiated coverage with buy rating and $10 target.
